We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Safety Study of GNbAC1 in Multiple Sclerosis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01639300
Recruitment Status : Completed
First Posted : July 12, 2012
Last Update Posted : February 8, 2021
Information provided by (Responsible Party):
GeNeuro SA ( GeNeuro Innovation SAS )

Brief Summary:

The purpose of this study is to assess the safety and tolerability of single ascending doses, as well as of repeated administrations of GNbAC1 in MS patients.

Scientific research has shown that the expression of genes of a virus which is integrated in the Human genetic material, the Multiple Sclerosis associated RetroVirus (MSRV) could play a critical role in the causation of multiple sclerosis.

GNbAC1 is an experimental medication, which neutralizes (i.e. inactivates) a protein of MSRV that might contribute to the development or deterioration of multiple sclerosis.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Biological: GNbAC1 Biological: GNbAC1 placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Randomised Placebo-Controlled Single Blind Study to Investigate Single Ascending Doses of GNbAC1 in Multiple Sclerosis Patients Followed by Open-label Extension With Repeated Doses of GNbAC1
Study Start Date : July 2012
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: GNbAC1 Biological: GNbAC1
Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg

Placebo Comparator: GNbAC1 placebo Biological: GNbAC1 placebo
Single dose intravenous (IV) GNbAC1 placebo

Primary Outcome Measures :
  1. To assess the safety and tolerability of single ascending doses, as well as of repeated administrations of GNbAC1 in MS patients. [ Time Frame: 177 days ]

Secondary Outcome Measures :
  1. To determine the pharmacokinetics (PK) characteristics following administration of single ascending doses, as well as of repeated administrations, of GNbAC1 in MS patients [ Time Frame: 177 days ]
  2. To determine pharmacodynamic markers of MS disease activity in patients including measurement of MSRV-Env markers and magnetic resonance imaging (MRI) [ Time Frame: 177 days ]
  3. To assess the immunogenicity of GNbAC1. [ Time Frame: 177 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients (if female, neither pregnant nor breast-feeding, should be post-menopausal or surgically sterile, or should use two highly effective method of contraception such as oral contraception plus mechanical barrier); Male subjects with partners of childbearing potential have to use adequate contraception during the study. Contraception methods should be followed during the study and up to 3 months after the last study drug administration. Female subjects who are women of childbearing potential (WOCBP) will have to be tested negative with a pregnancy test (serum or urine) at screening and Day 1 and before each repeated administrations of GNbAC1.
  • Between 18 and 65 years of age;
  • Patients with Primary Progressive MS (PPMS) according to the Revised McDonald criteria 2010 or patients with Secondary Progressive MS (SPMS) or patients with Relapsing-Remitting MS(RRMS)according to the Revised McDonald criteria 2010 who cannot be treated with available treatments for MS due to intolerance, non response or refusal of treatment;
  • Score ≤ 6.5 on the Expanded Disability Status Scale (EDSS);
  • Body weight between 40 and 100kg.

Exclusion Criteria:

  • Positive serology for viral hepatitis and HIV;
  • Disease other than MS that could better explain his/her signs and symptoms;
  • Previously treated with cladribine, lymphoid irradiation or depleting antibodies;
  • Usage in the last 3 months of interferon beta or glatiramer acetate;
  • Any usage in the last 6 months of mitoxantrone, cytotoxic immunosuppressive therapy, natalizumab, fingolimod or immunoglobulin;
  • Usage within 30 days prior to baseline of oral or systemic corticosteroids or ACTH;
  • Inadequate liver function;
  • Severe renal impairment;
  • Severe psychiatric disorder;
  • Known inability to undergo an MRI scan;
  • Having participated in another clinical study within 6 months prior to study baseline except for patients who have participated or who are currently participating in an interventional study without any study drug intake.
  • Pregnancy or breastfeeding
  • Female subjects considering becoming pregnant during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01639300

Layout table for location information
University Hospital Basel
Basel, Switzerland, 4031
Hopitaux Universitaires de Genève - HUG
Geneva, Switzerland, 1211
Sponsors and Collaborators
GeNeuro Innovation SAS
Layout table for investigator information
Principal Investigator: Tobias Derfuss, MD University Hospital, Basel, Switzerland
Principal Investigator: Patrice Lalive, MD HUG
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: GeNeuro Innovation SAS
ClinicalTrials.gov Identifier: NCT01639300    
Other Study ID Numbers: GNC-002
First Posted: July 12, 2012    Key Record Dates
Last Update Posted: February 8, 2021
Last Verified: February 2021
Keywords provided by GeNeuro SA ( GeNeuro Innovation SAS ):
Relapsing Forms of Multiple Sclerosis
Progressive Forms of Multiple Sclerosis
Monoclonal antibody
Multiple Sclerosis Associated Retrovirus (MSRV)
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases